The complexity of treatment discontinuation behavior in Drug-Resistant Tuberculosis (DR-TB) patients during Covid-19 pandemic era : A qualitative study in special region of Yogyakarta
Abstract
In 2017, there were 82 instances of drug-resistant tuberculosis in the Special Region of Yogyakarta, which is one of the regions with the highest incidence of tuberculosis (3,770 cases). Increases in mortality and Lost to Follow Up (LTFU) are affected by age, knowledge, psychological, and economic factors. TB and COVID-19 symptoms are nearly same, however there have not been as much research on COVID-19 infection in TB patients as during the COVID-19 epidemic. The purpose of this study is to determine the reasons why TB drug-resistant patients who are currently undergoing treatment abandon their regimens. A qualitative design with 5 respondents of TB drug-resistance discontinuation in the Special Region of Yogyakarta over the treatment period of 2022. Interviews, observations, and documentation were used to collect the data. Guidelines for interviews and observations, as well as documentation, are employed as instruments in this research. The data was examined using the seven coalition steps: transcripts, repeated readings, quotation, marking lines, codes, categories, and themes. There are 77 codes, 16 categories, and 4 themes as a consequence of the study. The psychological, spiritual, and economic element that is affected by psychological, spiritual, and economic management. Acceptant stage, function of roles, rewards, and assessment-based diagnosis influence the support system factor. The side effect of part is influenced by alternative treatments, biopsychology post-treatment, safety predominance, and the decision-making premise. The adaptability element is determined by the ability to decide one's own beliefs, the capacity for prevention, one's level of comfort, and the objectives of government programs. The termination of treatment in tuberculosis drug-resistant patients in the Special Region of Yogyakarta is influenced by psychosocial and economic factors, support networks, treatment side effects, and adaptation.
There is no Figure or data content available for this article
References
- Kemenkes RI. Infodatin Tuberkulosis. Pusat Data dan Informasi Kementerin Kesehatan RI; 2018.
- Migliori GB, Tiberi S, Zumla A, et al. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis. 2020;92:S15-S25. doi:10.1016/j.ijid.2020.01.042
- WHO. Consolidated Guidelines on Tuberculosis Treatment. World Health Organization “The End Of TB Strategy”; 2019.
- Widiastuti EN, Subroto YW, Pramono D. Determinan kejadian multi-drug resistant tuberculosis di rumah sakit Dr. Sardhito Yogyakarta. Ber Kedokt Masy (BKM J Community Med Public Heal. 2017;33(7):325-330.
- Dirjen PPPL Kemenkes RI. Tuberkulosis Multi-Drug Resistant. Kementrian Kesehatan Republik Indonesia. Published 2019. Accessed May 18, 2020. https://www.tbindonesia.or.id/page/view/22/tb-mdr
- Kementrian Kesehatan RI. Pedoman Nasional Pengendalian Tuberkulosis. Kementerian Kesehatan Republik Indonesia; 2014.
- Kumari A, Sharma PK, Kansal D, Bansal R, Kumari S. IJBCP International Journal of Basic & Clinical Pharmacology Original Research Article Socio-demographic profile of multi-drug resistant tuberculosis patients and its association with severity of adverse drug reactions in DOTS plus centre at tertiary hosp. 2018;7(12):2342-2346.
- Widyasrini ER, Probandari AN, - R. Factors Affecting the Success of Multi Drug Resistance (MDR-TB) Tuberculosis Treatment in Residential Surakarta. J Epidemiol Public Heal. 2017;02(01):45-57. doi:10.26911/jepublichealth.2017.02.01.05
- Saha A, Vaidya PJ, Chavhan VB, et al. Factors affecting outcomes of individualised treatment for drug resistant tuberculosis in an endemic region. Indian J Tuberc. 2019;66(2):240-246. doi:10.1016/j.ijtb.2017.04.001
- Mekonnen HS, Azagew AW. Non-adherence to anti-tuberculosis treatment, reasons and associated factors among TB patients attending at Gondar town health centers, Northwest Ethiopia 11 Medical and Health Sciences 1103 Clinical Sciences 11 Medical and Health Sciences 1117 Public Hea. BMC Res Notes. 2018;11(1):1-8. doi:10.1186/s13104-018-3789-4
- Udwadia Z, Furin J. Quality of drug-resistant tuberculosis care: Gaps and solutions. J Clin Tuberc Other Mycobact Dis. 2019;16:100101. doi:10.1016/j.jctube.2019.100101
- Harnilawati. Konsep Dan Proses Keperawatan Keluarga. 1st ed. (Amirullah, ed.). Pustaka As Salam; 2013.
- Reis J dos. Factors Associated with Medication Adherence among Tuberculosis Patients in Timor-Leste. Published online 2016.
- World Health Organization. What is Community System Strengthening?? Who are the Key Affected Populations in the context of TB?? What do Communities do in the TB response?? In: Stop TB Partnership. World Health Organization; 2014. http://www.stoptb.org/assets/documents/global/fund/COMMUNITY SYSTEM STRENGTHENING AND TB.pdf
- As’hab PP, Keliat BA. Faktor yang mempengaruhi kepatuhan klien terhadap pengobatan tuberkulosis resistan obat. J Ilmu Keperawatan Jiwa. 2020;3(2).
- World Health Organization (WHO). Companion Handbook: To the WHO Guidelines for the Programmatic Managment of Drug-Resistant Tuberculosis. World Health Organization; 2014. who.int
- World Health Organization. Tuberculosis and Covid-19: What Health Workers and Authorities Need to Know. Pan American Health Organization (PAHO). Published 2020. Accessed January 18, 2021. https://www.paho.org/hq/index.php?option=com_content&view=article&id=15759:tuberculosis-and-covid-19-what-health-workers-and-authorities-need-to-know&Itemid=1926&lang=en
- Aznar ML, Rando-Segura A, Moreno MM, et al. Prevalence and risk factors of multidrug-resistant tuberculosis in Cubal, Angola: A prospective cohort study. Int J Tuberc Lung Dis. 2019;23(1):67-72. doi:10.5588/ijtld.18.0231
- Morissan. Riset Kualitatif. In: Suraya, Harrid F, Bassar E, eds. Kencana; 2019.
- Palinkas LA, Horwitz SM, Green CA, et al. Purposeful sampling for qualitative data collection and analysis in mixed method implementation research. HHS Public Access. 2015;44(12):73. doi:10.1007/s10488-013-0528-y.Purposeful
- Moleong LJ. Metodologi Penelitian Kualitatif. PT. Remaja Rosdakarya; 2007.
- Saryono A. Metodologi penelitian kualitatif dan kuantitatif dalam bidang kesehatan. Yogyakarta Nuha Med. Published online 2013.
- McCann ZH, Szaflarski M, Szaflarski JP. A feasibility study to assess social stress and social support in patients enrolled in a cannabidiol (CBD) compassionate access program. Epilepsy Behav. 2021;124:108322.
- Daftary A, Mondal S, Zelnick J, et al. Dynamic needs and challenges of people with drug-resistant tuberculosis and HIV in South Africa: a qualitative study. Lancet Glob Heal. 2021;9(4):e479-e488. doi:https://doi.org/10.1016/S2214-109X(20)30548-9
- Morris MD, Quezada L, Bhat P, et al. Social, economic, and psychological impacts of MDR-TB treatment in Tijuana, Mexico: a patient’s perspective. Int J Tuberc Lung Dis. 2013;17(7):954-960. doi:10.5588/ijtld.12.0480
- Murray CJL, Ortblad KF, Guinovart C, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, England). 2014;384(9947):1005-1070. doi:10.1016/S0140-6736(14)60844-8
- Kumar BA. Rehabilitation of treated TB patients: Social, psychological and economic aspects. Int J Mycobacteriology. 2016;5:S129-S130. doi:https://doi.org/10.1016/j.ijmyco.2016.11.021
- Kaswa M, Minga G, Nkiere N, et al. The economic burden of TB-affected households in DR congo. Int J Tuberc Lung Dis. 2021;25(11):923-932. doi:10.5588/ijtld.21.0182
- Foster N, Vassall A, Cleary S, Cunnama L, Churchyard G, Sinanovic E. The economic burden of TB diagnosis and treatment in South Africa. Soc Sci Med. 2015;130:42-50. doi:https://doi.org/10.1016/j.socscimed.2015.01.046
- Solikhah MM, Nursasi AY, Wiarsih W. The relationship between family’s informational support and self-efficacy of pulmonary tuberculosis client. Enfermería Clínica. 2019;29:424-427. doi:10.1016/j.enfcli.2019.04.062
- Pallas SW, Courey M, Hy C, Killam WP, Warren D, Moore B. Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert(®) MTB/RIF for People Living with HIV/AIDS and People with Presumptive Multidrug-resistant Tuberculosis. Appl Health Econ Health Policy. 2018;16(4):537-548. doi:10.1007/s40258-018-0397-3
- Kübler-Ross E, Wessler S, Avioli L V. On death and dying. JAMA. 1972;221(2):174-179. doi:10.1001/jama.1972.03200150040010
- Vercoulen JH. A simple method to enable patient-tailored treatment and to motivate the patient to change behaviour. Chron Respir Dis. 2012;9(4):259-268. doi:10.1177/1479972312459974
- Salehitali S, Noorian K, Hafizi M, Dehkordi AH. Quality of life and its effective factors in tuberculosis patients receiving directly observed treatment short-course (DOTS). J Clin Tuberc Other Mycobact Dis. 2019;15:100093. doi:https://doi.org/10.1016/j.jctube.2019.100093
- Ethiopia Ministry of Health. Guidelines For Management of TB, DR-TB and Leprosy In Ethiopia. 6th ed. Addis Ababa; 2018.
- Widyasrini ER, Probandari AN, Reviono. Factors Affecting the Success of Multi Drug Resistance (MDR-TB) Tuberculosis Treatment in Residential Surakarta. J Epidemiol Public Heal. 2017;02(01):45-57. doi:10.26911/jepublichealth.2017.02.01.05
- Tristiana RD, Kumalasari R, Makhfudli M. Pengalaman Klien TB Paru yang Menjalani Pengobatan Fase Intensif di Puskesmas Taji Kabupaten Magetan. Indones J Community Heal Nurs. 2019;4(1):1. doi:10.20473/ijchn.v4i1.12353
- Schwardmann P. Motivated health risk denial and preventative health care investments. J Health Econ. 2019;65:78-92. doi:10.1016/j.jhealeco.2019.01.005
- Kementrian Kesehatan RI. Petunjuk Teknis Manajemen Terpadu Pengendalian Resistan Obat.; 2014.
- Bada FO, Blok N, Okpokoro E, et al. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria. PLoS One. 2020;15(12):e0241065. doi:10.1371/journal.pone.0241065
How to Cite This
Copyright and Permissions
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.